<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00813124</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0087</org_study_id>
    <secondary_id>NCI-2012-02122</secondary_id>
    <nct_id>NCT00813124</nct_id>
  </id_info>
  <brief_title>Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)</brief_title>
  <official_title>Azacitidine Maintenance Therapy After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia (CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to&#xD;
      patients with CML after an donor stem cell transplant will increase the likelihood of&#xD;
      achieving a complete remission of CML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug:&#xD;
&#xD;
      Azacitidine is designed to block genes in cancer cells that stop the function of the&#xD;
      tumor-fighting genes. By blocking the &quot;bad&quot; genes, the tumor-fighting genes may be able to&#xD;
      work better.&#xD;
&#xD;
      Study Drug Administration and Procedures before the Stem Cell Transplant:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be given chemotherapy&#xD;
      before the transplant of donor cells. The chemotherapy is designed to kill leukemia cells and&#xD;
      will also block your body's ability to reject the donor cells that will be given to you&#xD;
      during the transplant. You will receive the chemotherapy on the days before the transplant.&#xD;
      You will receive the transplant on Day 0.&#xD;
&#xD;
      This low-level test dose of busulfan is to check how fast busulfan is processed by your body&#xD;
      and cleared from your blood. This information will help the doctor decide the dose of&#xD;
      busulfan you will receive. You may receive the busulfan test dose as an outpatient during the&#xD;
      week before you are admitted to the hospital or as an inpatient on Day -8 (8 days before your&#xD;
      stem cell transplant).&#xD;
&#xD;
      About 11 samples of blood (about 1 teaspoon each time) will be drawn for pharmacokinetic (PK)&#xD;
      testing. PK testing measures the amount of study drug in the body at different time points.&#xD;
      These blood samples will be drawn at various times before you receive busulfan and over the&#xD;
      next 11 hours. These blood draws will be repeated again on the first day of high-dose&#xD;
      busulfan treatment (Day -5).&#xD;
&#xD;
      A heparin lock line (small IV line) will be placed in your vein to lower the number of needle&#xD;
      sticks needed for these draws. If it is not possible for the PK tests to be performed for&#xD;
      technical or scheduling reasons, you will receive the standard fixed dose of busulfan.&#xD;
&#xD;
      On Days -5 through -2, you will receive fludarabine by vein over 1 hour, then busulfan by&#xD;
      vein over 3 hours.&#xD;
&#xD;
      If you are going to be receiving a transplant from an unrelated donor, or if you have a donor&#xD;
      that is mismatched, you will also receive antithymocyte globulin (ATG) by vein over 4 hours&#xD;
      on the 3 days before the transplant. This drug is designed to further weaken your immune&#xD;
      system to reduce the risk of rejecting of the transplant.&#xD;
&#xD;
      Stem Cell Transplant:&#xD;
&#xD;
      After the blood-forming cells are collected from the donor, they will be given to you by&#xD;
      vein. You will be given standard drugs to help decrease the risk of side effects. You may ask&#xD;
      the study staff for information about how the drugs are given and their risks.&#xD;
&#xD;
      Drugs to Prevent Infections:&#xD;
&#xD;
      You will receive several drugs to help the stem cell transplant work and to help decrease the&#xD;
      risks of infections while your immune system is weak. Tacrolimus and methotrexate will be&#xD;
      given to decrease the risk of graft-versus-host disease (GVHD), a problem that may occur if&#xD;
      the donor's immune cells fight your body.&#xD;
&#xD;
        -  Tacrolimus will be started 2 days before the transplant and will continue for as long as&#xD;
           your doctor thinks is necessary. This is usually 3-12 months, but may be longer if you&#xD;
           develop GVHD. Tacrolimus is given by vein non-stop until you are able to eat. Once you&#xD;
           can eat, it will be given by mouth.&#xD;
&#xD;
        -  Methotrexate is given by vein over about 15-30 minutes on Days 1, 3, 6, and 11.&#xD;
&#xD;
      Several drugs will also be given to decrease the risk of other infections. Some of these&#xD;
      antibiotics are given by vein, and some are given as pills. The length of time that you will&#xD;
      take the antibiotics will vary. Your doctor will describe this to you in more detail.&#xD;
&#xD;
      Study Drug Administration after the Stem Cell Transplant:&#xD;
&#xD;
      You will receive azacitidine as an injection under the skin once a day over 5 days in a row,&#xD;
      starting about 5 weeks after the transplant. This may be repeated once a month for up to 4&#xD;
      months after the transplant. You will have about 23 days of &quot;rest&quot; between each cycle of&#xD;
      treatment (a cycle is the period of 28 days). If intolerable side effects occur, treatment&#xD;
      with azacitidine may be interrupted or stopped altogether.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      You will be in the hospital for about 3-4 weeks after the transplant. You will have check-ups&#xD;
      every day until you leave the hospital. After you leave, the number of study visits will&#xD;
      vary, depending on your condition.&#xD;
&#xD;
      You will have bone marrow aspirations collected before chemotherapy, around 1, 6, and 12&#xD;
      months after the transplant. To collect a bone marrow aspirate, an area of the hip bone is&#xD;
      numbed with anesthetic, and a small amount of bone marrow is withdrawn through a large&#xD;
      needle. The bone marrow samples will be used to check the status of the disease and to learn&#xD;
      the way azacitidine works.&#xD;
&#xD;
      Blood (about 2 teaspoons each time) will be drawn to learn about patterns of a process called&#xD;
      methylation. Methylation is a process by which the body may turn &quot;on and off&quot; certain genes.&#xD;
      Blood will be drawn at the following times:&#xD;
&#xD;
        -  At baseline.&#xD;
&#xD;
        -  Before the stem cell transplant (Day 0).&#xD;
&#xD;
        -  Six (6), 9, and 12 months after the transplant.&#xD;
&#xD;
        -  Before you receive your first dose of azacitidine (Day 1 of each cycle).&#xD;
&#xD;
        -  After you receive the last dose of azacitidine (Day 5 of each cycle).&#xD;
&#xD;
      Blood (about 8 teaspoons each time) will be drawn to learn about the body's immune system&#xD;
      recovery, at the following times:&#xD;
&#xD;
        -  Cycle 1- Day 1&#xD;
&#xD;
        -  Cycle 1 - Day 14&#xD;
&#xD;
        -  Cycle 3 - Day 1&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You will remain on study for up to 1 year. You may be taken off study early if the disease&#xD;
      gets worse or intolerable side effects occur.&#xD;
&#xD;
      This is an investigational study. Azacitidine is FDA approved and commercially available in&#xD;
      patients with myelodysplastic syndrome. Its use in patients with CML is investigational. All&#xD;
      other drugs used in this study are FDA approved and commercially available.&#xD;
&#xD;
      Up to 57 patients will take part in this study. All will be enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Molecular Response</measure>
    <time_frame>12 month post BMT</time_frame>
    <description>Molecular Remission defined as two consecutive bone marrow samples done one month apart with negative PCR( polymerase chain reaction) tor CML.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.</description>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <other_name>Fludarabine Phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).</description>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.</description>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <other_name>Antithymocyte globulin</other_name>
    <other_name>ATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.</description>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <other_name>5-Azacitidine</other_name>
    <other_name>5-Aza</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>NSC-102816</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell infusion on day 0 administered by vein after collected from donor.</description>
    <arm_group_label>Azacytidine Maintenance after allotx</arm_group_label>
    <other_name>allotx</other_name>
    <other_name>allogeneic stem cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with age &lt;= 75 years with CML in first chronic phase, which has failed to&#xD;
             achieve a cytogenetic or molecular complete remission or has progressed after imatinib&#xD;
             treatment. Criteria for failure are the international consensus criteria (Appendix H).&#xD;
             Patients intolerant to tyrosine kinase inhibitor therapy are also eligible.&#xD;
&#xD;
          2. Patients with age &lt;= 75 with CML in accelerated phase or blast crisis that have &lt;= 15%&#xD;
             blasts in the blood and bone marrow at study entry.&#xD;
&#xD;
          3. Donor: HLA-compatible related (HLA-A, -B, -DRB1 matched or with one-antigen mismatch)&#xD;
             or HLA-compatible unrelated (HLA-A, -B, -C and -DRB1 matched or with one-antigen&#xD;
             mismatch).&#xD;
&#xD;
          4. Age 18 to 75 years.&#xD;
&#xD;
          5. Zubrod performance status &lt;= 2.&#xD;
&#xD;
          6. Left ventricular ejection fraction =&gt; 40%.&#xD;
&#xD;
          7. Pulmonary function test within the following parameters: forced expiratory volume at&#xD;
             one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for&#xD;
             carbon monoxide (DLCO) =&gt; 50% of expected, corrected for hemoglobin.&#xD;
&#xD;
          8. Serum creatinine &lt; 1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min.&#xD;
&#xD;
          9. Serum direct bilirubin &lt; 1.5 mg/dL (unless Gilbert's syndrome)&#xD;
&#xD;
         10. Serum glutamate pyruvate transaminase (SGPT) &lt;= 200 IU/L unless related to patient's&#xD;
             malignancy.&#xD;
&#xD;
         11. Patients treated with any tyrosine kinase inhibitor, interferon or any experimental&#xD;
             therapy are eligible.&#xD;
&#xD;
         12. Patients with age &lt;75 years with CML in second or subsequent chronic phase.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled infection, not responding to appropriate antimicrobial agents after seven&#xD;
             days of therapy.&#xD;
&#xD;
          2. Pleural/pericardial effusion or ascites estimated to be &gt;1L.&#xD;
&#xD;
          3. HIV-positive.&#xD;
&#xD;
          4. Breast feeding or pregnancy. Pregnancy means a positive beta human chorionic&#xD;
             gonadotropin (HCG) test in a woman with child bearing potential defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization.&#xD;
&#xD;
          5. Known or suspected hypersensitivity to azacitidine or mannitol.&#xD;
&#xD;
          6. Patients with advanced malignant hepatic tumors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Champlin, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>December 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 7, 2021</results_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Donor stem cell transplant</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Stem cell transplant</keyword>
  <keyword>ATG</keyword>
  <keyword>Antithymocyte globulin</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>5-Azacitidine</keyword>
  <keyword>5-Aza</keyword>
  <keyword>5-AZC</keyword>
  <keyword>Ladakamycin</keyword>
  <keyword>NSC-102816</keyword>
  <keyword>allotx</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Fludarabine Phosphate</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Azacitidine maintenance therapy</keyword>
  <keyword>molecular remission</keyword>
  <keyword>HLA compatible donor</keyword>
  <keyword>Engraftment</keyword>
  <keyword>Chimerism</keyword>
  <keyword>Graft vs host disease</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 17, 2008 to February 27, 2014. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Azacitidine Post Transplant</title>
          <description>Fludarabine 40 mg/m^2 intravenous (IV) Day -5 to Day -2; Busulfan dose calculated to achieve area under curve (AUC) of 4000 µMol-min + 12% based on pharmacokinetic studies (days -5, -4, -3, and -2); Thymoglobulin: 2.5 mg/kg IV on Day -3 to Day -1; Azacitidine 32 mg/m^2 subcutaneous daily for 5 days starting 5 weeks after transplant, repeated monthly up to 4 months. Allogeneic stem cell infusion (allotx) on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible - Participants did not received Azacytidine</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azacytidine Maintenance After Allotx</title>
          <description>Fludarabine 40 mg/m^2 intravenous (IV) Day -5 to Day -2; Busulfan dose calculated to achieve area under curve (AUC) of 4000 µMol-min + 12% based on pharmacokinetic studies (days -5, -4, -3, and -2); Thymoglobulin: 2.5 mg/kg IV on Day -3 to Day -1; Azacitidine 32 mg/m^2 subcutaneous daily for 5 days starting 5 weeks after transplant, repeated monthly up to 4 months. Allogeneic stem cell infusion (allotx) on day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Molecular Response</title>
        <description>Molecular Remission defined as two consecutive bone marrow samples done one month apart with negative PCR( polymerase chain reaction) tor CML.</description>
        <time_frame>12 month post BMT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azacytidine Maintenance After Allotx</title>
            <description>Fludarabine 40 mg/m^2 intravenous (IV) Day -5 to Day -2; Busulfan dose calculated to achieve area under curve (AUC) of 4000 µMol-min + 12% based on pharmacokinetic studies (days -5, -4, -3, and -2); Thymoglobulin: 2.5 mg/kg IV on Day -3 to Day -1; Azacitidine 32 mg/m^2 subcutaneous daily for 5 days starting 5 weeks after transplant, repeated monthly up to 4 months. Allogeneic stem cell infusion (allotx) on day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Molecular Response</title>
          <description>Molecular Remission defined as two consecutive bone marrow samples done one month apart with negative PCR( polymerase chain reaction) tor CML.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected through four treatment cycles of 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azacytidine Maintenance After Allotx</title>
          <description>Fludarabine 40 mg/m^2 intravenous (IV) Day -5 to Day -2; Busulfan dose calculated to achieve area under curve (AUC) of 4000 µMol-min + 12% based on pharmacokinetic studies (days -5, -4, -3, and -2); Thymoglobulin: 2.5 mg/kg IV on Day -3 to Day -1; Azacitidine 32 mg/m^2 subcutaneous daily for 5 days starting 5 weeks after transplant, repeated monthly up to 4 months. Allogeneic stem cell infusion (allotx) on day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Delayed engraftment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Low granulocyte</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Low platelet</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Low granulocyte</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flu like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Low platelet</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>T bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Broncholitis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard E. Champlin, MD/Chair, Stem Cell Transplantation</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-3618</phone>
      <email>rchampli@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

